NYSE$NEUE
NeueHealth Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Delivered strongest financial performance driven by NeueCare and NeueSolutions, achieving positive Adjusted EBITDA for the third consecutive quarter and reaffirming full-year Adjusted EBITDA guidance.
NeueHealth reported strong financial results for Q3 2024, driven by positive momentum in NeueCare and NeueSolutions. The company achieved Adjusted EBITDA profitability for the third consecutive quarter and reaffirmed its full-year Adjusted EBITDA guidance.
- Delivered strongest financial performance to date in Q3 ‘24, resulting from continued positive momentum in NeueCare and NeueSolutions business segments
- Drove positive Adjusted EBITDA for the third consecutive quarter in 2024
- Reaffirming Adjusted EBITDA guidance for the full year
- Well-positioned to build on success and capitalize on strategic growth opportunities in 2025 and beyond
Headline financials
Revenue & EPS history
NeueHealth · Revenue · Quarterly
$233M
Forward guidance
NeueHealth reaffirms its financial outlook for 2024.
Tailwinds
- Revenue is expected to be approximately $950 million
- NeueCare Revenue is expected to be approximately $320 million
- NeueSolutions Revenue is expected to be approximately $640 million
- Adjusted Operating Cost Ratio is expected to be between 15% and 16%, excluding corporate costs.
- Including corporate costs, this is expected to be between 19% and 20%
- Adjusted EBITDA is expected to be between $15 million and $25 million in 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-2.0%
Avg return
Earnings day
-6.9%
Avg return
5 days after
-17.7%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+46.5%
Q1 2023
Best reaction
-43.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | -2.2% | -2.1% | |
| Q1 2025 | -2.2% | -0.4% | -1.5% | |
| Q4 2024 | +8.9% | +30.9% | +29.9% | |
| Q3 2024 | +2.2% | +2.5% | +7.8% | |
| Q2 2024 | -3.6% | +2.3% | -4.4% | |
| Q1 2024 | -4.0% | -3.7% | -14.3% | |
| Q4 2023 | +7.6% | -6.0% | -27.7% | |
| Q3 2023 | -1.5% | -10.2% | -15.5% | |
| Q2 2023 | -21.8% | -27.8% | -61.3% | |
| Q1 2023 | +46.5% | +7.2% | -14.1% | |
| Q4 2022 | -43.1% | -48.8% | -77.2% | |
| Q3 2022 | +4.3% | -3.7% | -15.3% | |
| Q2 2022 | -9.3% | +2.1% | -15.1% | |
| Q1 2022 | +35.7% | +26.0% | -0.6% | |
| Q4 2019 | -2.6% | -1.3% | -16.4% | |
| Q4 2021 | -29.5% | -42.9% | -35.6% | |
| Q3 2020 | +1.3% | -13.1% | -15.4% | |
| Q3 2021 | -35.1% | -34.4% | -40.5% | |
| Q2 2020 | +5.1% | — | — | |
| Q1 2021 | +5.1% | — | — | |
| Q4 2020 | +5.1% | — | — | |
| Q2 2021 | -13.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro